Reducing Life-threatening and Disabling Hemorrhagic Conditions
Our patented technology aims to address unmet medical needs by using an innovative mechanism of action to inhibit fibrinolysis.
A Novel Antifibrinolytic Strategy
Hemostatics is developing CM-352, a novel antifibrinolytic agent to reduce bleeding in life-threatening and disabling hemorrhagic conditions.
With a new mechanism of action to inhibit fibrinolysis, our patented preclinical candidate is addressing significant unmet medical needs (e.g. IntraCranial Hemorrhage where other treatments are still suboptimal).
A Novel Antifibrinolytic Strategy
With a new mechanism of action to inhibit fibrinolysis, our patented preclinical candidate is addressing significant unmet medical needs (e.g. IntraCranial Hemorrhage where other treatments are still suboptimal).
Targeted Conditions
Surgery
Major Surgeries
Significant blood loss occurs in 3% of the 100-120 millions of major surgeries every year in the 7 major markets. Cardiac surgery is the largest consumer of blood transfusion products.
Trauma
Trauma
Hemorrhage is responsible of 45% of deaths occurring within 24h after traumatic injury.
ICH
IntraCerebral Hemorrhage
IntraCerebral Hemorrhage (ICH) accounts for approx. 20% of all strokes, with a case fatality rate of 54% at 1 year. There is currently no treatment to stop hemorrhage or prevent hemorrhage enlargement.
Gynecology
GYNECOLOGY
Several gynecological conditions are caused by an excess of bleeding (Heavy Menstrual Bleeding, Postpartum Bleeding, Cesaren, etc.).
RARE DISEASES
RARE DISEASES
Several Bleeding Disorders are associated with hemorrhage (Hereditary Angioedema, Hemophilia, etc.).
GI BLEEDING
GASTROINTESTINAL BLEEDING
Acute gastrointestinal (GI) bleeding is a potentially life-threatening emergency and common cause of hospitalization.
We Partner With Leading Experts in the Fields of Science, Healthcare, and Business
Exceptional Accomplishments Power the Holistic Success of Hemostatics
4
PATENTS
Strong IP position: 3 patents on novel drug formulas and 1 patent protecting the mechanism against known inhibitors repositioning.
89%
BLEEDING TIME DECREASE
CM-352 reduces Bleeding Time in mice by 89%.
61%
BLOOD LOSS DECREASE
CM-352 reduces Blood Loss by 61% in a Tail Bleeding mice model.
4
PRECLINICAL MODELS
Efficacious in 4 different preclinical animal models of bleeding. Optimal profile for i.v. administration, ideal for short term control of bleeding.